According to NVS’ 2Q11 CC, the Elinogrel phase-3 trial in ACS (#msg-53876832) is on hold until NVS sees the FDA response to the Brilinta NDA, which has a PDUFA date today.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”